Makes Nuplazid for Parkinson's-disease psychosis and Daybue for Rett syndrome, with a CNS-focused pipeline.
Makes Nuplazid for Parkinson's-disease psychosis and Daybue for Rett syndrome, with a CNS-focused pipeline.
Sells both drugs in the US through specialty pharmacies, paid prescription by prescription by insurers. Nuplazid, on sale since 2016, carries most of the revenue, and Daybue, launched in 2023, is the newer line. Daybue is licensed from Neuren Pharmaceuticals, to which Acadia pays royalties.
Moat: narrow (IP / patents, regulatory licence). Orphan-drug exclusivity and being first-approved in each indication limit near-term competition.
Headquarters: San Diego, California, US · Founded: 1993 · Employees: 798
Size ACADIA Pharmaceuticals (ACAD) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.08B, the 1522nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.83 on 18 Nov 2026.
Performance Over six months the shares fell 14.9%, against +1.9% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 14.8% over the last twelve months (peer median +25.3%); the operating margin is 10.2% (peer median 14.8%).
Valuation It trades at 17.8× forward earnings against a peer median of 22.1× (6th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.7 points above its cost of capital (9.3% WACC).
Short interest Short interest is 4.8% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.20B | $1.07B | $958M | $726M | $517M |
| Revenue growth | — | +12% | +32% | +40% | — |
| Gross profit | $1.09B | $972M | $861M | $681M | $507M |
| EBITDA | $135M | $117M | $100M | -$67.8M | -$222M |
| Net income | $362M | $391M | $226M | -$61.3M | -$216M |
| Free cash flow | $82.0M | $105M | $157M | $16.7M | -$114M |
| Capital expenditure | $15.5M | $104M | $523,000 | $40.0M | $0 |
| Total debt | $71.9M | $52.2M | $52.0M | $57.2M | $62.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals ACAD | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% |
| Neurocrine Biosciences NBIX | $16.5B | +5% | +38% | 25% | 18.0× | -1.5% |
| Supernus Pharmaceuticals SUPN | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% |
| Biogen BIIB | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% |
| Jazz Pharmaceuticals Public JAZZ | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ACAD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.8% | -0.1% | 5th lowest of 21 |
| 6-month return | -14.9% | +1.9% | 6th lowest of 21 |
| Distance from 52-week high | -42.4% | -19.4% | 5th lowest of 21 |
| Revenue growth (TTM) | +14.8% | +25.3% | 10th lowest of 20 |
| Operating margin | 10.2% | 14.8% | 9th lowest of 19 |
| Forward P/E | 17.8× | 22.1× | 6th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 9.2% | -0.5% | 5th most demanding of 13 |
| Growth delivered (Del g) | +19.4% | +8.8% | 4th highest of 13 |
| Hurdle (Req g minus delivered) | -10.1 pp | -14.0 pp | 5th most demanding of 13 |
| ROIC minus cost of capital | +10.7 pp | +5.7 pp | 6th highest of 17 |
| EV / EBITDA | 16.1× | 30.7× | 3rd cheapest of 10 |
| Net debt / EBITDA | -6.7× | -0.8× | 2nd least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% | +2.7% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 63.4× | n/a | n/a |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% | +2.4% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |